Shattuck Labs, Inc. (STTK)
Shattuck Labs, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Austin, TX, US. The stock last traded at $7.18, up 0.56% on the session, giving a market capitalisation of $648.9M. On trailing twelve-month figures it carries a trailing P/E of -14.08, a net margin of -5256.8%. Its beta of 1.11 implies it has historically moved more than the broad market.
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.
Shattuck Labs, Inc. is most often compared with the following Healthcare names: